drugset / Trial / NCT02633839

A Study of the Safety and Levodopa Pharmacokinetics Following Single Dose Administration of CVT 301 (Levodopa Inhalation Powder) in Smoking and Non-Smoking Adults

NCT02633839

Phase 1 Completed 60 enrolled Acorda Therapeutics
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is an open label, parallel group study to evaluate the pharmacokinetics (PK) and safety of a single dose of CVT-301 in smoking and non-smoking adults.

Timeline

Start
2015-12
Primary completion
2016-04
Completion
2016-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Levodopa Small molecule Inhaled
Background Carbidopa Unknown Oral

Indications

No indication recorded.